Trial Profile
A Phase II, Open-lable, Single Center Study to Evaluate the Efficacy and Safety of Palbociclib for the Treatment of Retinoblastoma Protein-Expressing Germ Cell Tumors.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 04 Apr 2016
Price :
$35
*
At a glance
- Drugs Palbociclib (Primary)
- Indications Germ cell and embryonal neoplasms; Germ cell cancer
- Focus Therapeutic Use
- 02 Dec 2015 New trial record